Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C17H19N3.C4H4O4 |
| Molecular Weight | 381.425 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.[H][C@]12CN(C)CCN1C3=C(CC4=C2C=CC=C4)C=CC=N3
InChI
InChIKey=RPUBHMMISKEXSR-MLCLTIQSSA-N
InChI=1S/C17H19N3.C4H4O4/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20;5-3(6)1-2-4(7)8/h2-8,16H,9-12H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t16-;/m1./s1
| Molecular Formula | C4H4O4 |
| Molecular Weight | 116.0722 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
| Molecular Formula | C17H19N3 |
| Molecular Weight | 265.3529 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Esmirtazapine (S-(+)mirtazapine or ORG-50081) is an enantiomer of mirtazapine (REMERON®), a high-affinity antagonist at 5-HT2/5-HT3 and H1 receptors, used in the treatment of depression. Esmirtazapine has a shorter plasma half-life than the R(−) enantiomer. Esmirtazapine is preferentially metabolized into an 8-hydroxy glucuronide. Organon was developing esmirtazapine for the treatment of hot flushes (vasomotor symptoms) associated with the menopause and insomnia.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Third-generation antidepressants: do they offer advantages over the SSRIs? | 2001 |
|
| Behavioral disturbances in dementia. | 2003 Mar |
|
| Hypertensive urgency with clonidine and mirtazepine. | 2004 Sep-Oct |
|
| Mirtazapine (Remeron) as treatment for non-mechanical vomiting after gastric bypass. | 2005 May |
|
| Mirtazepine for MDMA-induced depression. | 2005 May-Jun |
|
| Chiral resolution and binding study of 1,3,4,14b-tetrahydro-2,10-dimethyl-2H,10H-pyrazino[2,1-d]pyrrolo[1,2-b] [1,2,5]benzotriazepine (10-methyl-10-azaaptazepine) and 2-methyl-1,3,4,14b-tetrahydro-2H-pyrazino[2,1-d]pyrrolo[1,2-b] [1,2,5]benzothiadiazepine 10,10-dioxide (tiaaptazepine). | 2005 Nov-Dec |
|
| Post-traumatic stress disorder. | 2007 Aug 1 |
|
| In silico prediction of pregnane X receptor activators by machine learning approaches. | 2007 Jan |
|
| Triple reuptake inhibitors: the next generation of antidepressants. | 2008 Dec |
|
| Pharmacological management of panic disorder. | 2008 Feb |
|
| Neuropharmacology. | 2008 Oct |
|
| Triple reuptake inhibitors: a premise and promise. | 2008 Sep |
|
| Brain-derived neurotrophic factor: role in depression and suicide. | 2009 |
|
| Psychopharmacology of ADHD in pediatrics: current advances and issues. | 2009 |
|
| Brain potentials of conflict and error-likelihood following errorful and errorless learning in obsessive-compulsive disorder. | 2009 Aug 12 |
|
| Early presentation following overdose of modified-release paracetamol (Panadol Osteo) with biphasic and prolonged paracetamol absorption. | 2009 Aug 7 |
|
| Treatment with selective serotonin reuptake inhibitors and mirtapazine results in differential brain activation by visual erotic stimuli in patients with major depressive disorder. | 2009 Jun |
|
| Undertreatment of menopausal symptoms and novel options for comprehensive management. | 2009 Nov |
|
| Algorithms for the assessment and management of insomnia in primary care. | 2009 Nov 3 |
|
| Sexual side-effects of contemporary antidepressants: review. | 2009 Sep |
|
| Extreme thermal sensitivity and pain-induced sensitization in a fibromyalgia patient. | 2010 |
|
| Comorbidities of migraine. | 2010 |
|
| Gene expression profiling in whole blood identifies distinct biological pathways associated with obesity. | 2010 Dec 1 |
|
| Behavioral and developmental changes in rats with prenatal exposure of mirtazapine. | 2010 Jul-Sep |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:45:52 GMT 2023
by
admin
on
Fri Dec 15 15:45:52 GMT 2023
|
| Record UNII |
I2U18E6JKA
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29756
Created by
admin on Fri Dec 15 15:45:52 GMT 2023 , Edited by admin on Fri Dec 15 15:45:52 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DBSALT001294
Created by
admin on Fri Dec 15 15:45:52 GMT 2023 , Edited by admin on Fri Dec 15 15:45:52 GMT 2023
|
PRIMARY | |||
|
6451144
Created by
admin on Fri Dec 15 15:45:52 GMT 2023 , Edited by admin on Fri Dec 15 15:45:52 GMT 2023
|
PRIMARY | |||
|
CHEMBL1366933
Created by
admin on Fri Dec 15 15:45:52 GMT 2023 , Edited by admin on Fri Dec 15 15:45:52 GMT 2023
|
PRIMARY | |||
|
RR-49
Created by
admin on Fri Dec 15 15:45:52 GMT 2023 , Edited by admin on Fri Dec 15 15:45:52 GMT 2023
|
PRIMARY | |||
|
680993-85-5
Created by
admin on Fri Dec 15 15:45:52 GMT 2023 , Edited by admin on Fri Dec 15 15:45:52 GMT 2023
|
PRIMARY | |||
|
C76940
Created by
admin on Fri Dec 15 15:45:52 GMT 2023 , Edited by admin on Fri Dec 15 15:45:52 GMT 2023
|
PRIMARY | |||
|
100000174954
Created by
admin on Fri Dec 15 15:45:52 GMT 2023 , Edited by admin on Fri Dec 15 15:45:52 GMT 2023
|
PRIMARY | |||
|
I2U18E6JKA
Created by
admin on Fri Dec 15 15:45:52 GMT 2023 , Edited by admin on Fri Dec 15 15:45:52 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |